Cerus Corporation
A blood-safety company based in Concord, California, Cerus makes the INTERCEPT Blood System, a technology used by blood banks to zap donated platelets and plasma with UV light and a compound called amotosalen, neutralizing viruses, bacteria, and parasites before they reach patients. Founded in 1991 by hematologist Laurence Corash and chemist John Hearst, the company spun off its immunotherapy business in 2007 to focus on blood safety. Its product is aptly named: the system "intercepts" pathogens by cross-linking their DNA so they can't reproduce, rather than just screening for known ones.
Granted 3.23M · Sold 929.8K
Granted 106.7K · Sold 28.4K
Granted 1.42M · Sold 406.4K
Granted 1.28M · Sold 495.9K
Granted 1.04M · Sold 410.2K
Granted 876.4K · Sold 446.4K
Granted 160.0K
Granted 86.7K · Sold 20.6K
Granted 160.0K · Bought 20.0K
Granted 160.0K · Bought 2.0K
Granted 160.0K · Bought 10.0K · Sold 40.5K
Granted 160.0K
Granted 100.0K · Bought 2.5K
Granted 100.0K
Granted 160.0K · Bought 2.5K
Granted 40.0K
Granted 120.0K · Bought 26.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Greenman William MarinerPresident and CEO, Director · 15 transactions | +91% | 5.00M | 3.23M | — | 929.8K |
| Corash Laurence MChief Scientific Officer · 4 transactions | +3.5% | 2.34Mas of Mar 2024 | 106.7K | — | 28.4K |
| Jayaraman Vivek KChief Operating Officer · 17 transactions | +158.1% | 1.66M | 1.42M | — | 406.4K |
| Green Kevin DennisChief Financial Officer · 20 transactions | +194.1% | 1.24M | 1.28M | — | 495.9K |
| Jensen ChrystalChief Legal Officer · 19 transactions | — | 1.15M | 1.04M | — | 410.2K |
| Benjamin Richard JChief Medical Officer · 20 transactions | +123.7% | 777.4K | 876.4K | — | 446.4K |
| Menard ChrystalChief Legal Officer · 1 transaction | +50.5% | 509.5Kas of Mar 2024 | 160.0K | — | — |
| Moore CarolSVP Reg. & Quality · 4 transactions | +20.5% | 501.0Kas of Mar 2024 | 86.7K | — | 20.6K |
| Witney FrankDirector · 4 transactions | +112.5% | 340.1K | 160.0K | 20.0K | — |
| Nachtsheim Jami KDirector · 4 transactions | +152.3% | 268.4K | 160.0K | 2.0K | — |
| Bjerkholt EricDirector · 6 transactions | +98% | 261.7K | 160.0K | 10.0K | 40.5K |
| Lucena AnnDirector · 3 transactions | +221.3% | 232.3K | 160.0K | — | — |
| Swisher Daniel N JRDirector · 3 transactions | +98% | 207.0Kas of Jun 2025 | 100.0K | 2.5K | — |
| Moore Timothy L.Director · 2 transactions | +95.2% | 205.1Kas of Jun 2025 | 100.0K | — | — |
| Shan HuaDirector · 4 transactions | — | 192.4K | 160.0K | 2.5K | — |
| Schulze GailDirector · 1 transaction | +32.4% | 163.4Kas of Jun 2024 | 40.0K | — | — |
| Gregory Dean A.Director · 4 transactions | — | 146.7K | 120.0K | 26.7K | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 3 years: -2.71M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.